key: cord-0952575-1kijiu1h authors: Lopez Bernal, J.; Andrews, N.; Gower, C.; Stowe, J.; Tessier, E.; Simmons, R.; Ramsay, M. title: Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19 date: 2021-05-18 journal: nan DOI: 10.1101/2021.05.14.21257218 sha: 848b1614302f57f4988cc142a9db89a4fed8aa19 doc_id: 952575 cord_uid: 1kijiu1h We estimated risk of death in vaccinated compared to unvaccinated COVID-19 cases. Cases vaccinated with 1 dose of BNT162b2 had 44% reduced risk of death, 55% with 1 dose of ChAdOx1, and 69% with 2 doses of BNT162b2. This is on top of the protection provided against becoming a case. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) f i r s t t o e s t i m a t e f o r t h e e f f e c t i v e n e s s o f C h A d O x 1 a g a i n s t m o r t a l i t y a n d s u g g e s t s t h a t a s i n g l e d o s e o f f e r s s i m i l a r l e v e l s o f p r o t e c t i o n t o B N T 1 6 2 b 2 . W e f o u n d t h a t a l t h o u g h b o t h v a c c i n e s p r o v i d e d a d d i t i o n a l p r o t e c t i o n a g a i n s t m o r t a l i t y o v e r a l l , a m o n g c a r e h o m e r e s i d e n t s w h o r e c e i v e d a s i n g l e d o s e o f t h e P f i z e r v a c c i n e , t h e e f f e c t w a s s m a l . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.14.21257218 doi: medRxiv preprint Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study) BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. The New England journal of medicine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Technical summary: Public Health England data series on deaths in people with COVID-19 2020 COVID-19 -high risk shielded patient list identification methodology 2020 Public Health England vaccine effectiveness report -March 2021: Public Health England Nationwide Vaccination Campaign with BNT162b2 in Israel Demonstrates High Vaccine Effectiveness and Marked Declines in Incidence of SARS-CoV-2 Infections and COVID-19 Cases, Hospitalizations, and Deaths